Price
Target price
€60.24
€60.24
-1.340%
-0.82
-1.340%
€70.40
20.02.26 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
We can see a decrease in the price for Halozyme Therapeutics Inc.. Compared to yesterday it has lost -€0.820 (-1.340%).
With 20 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 70 € there is a slightly positive potential of 16.2% for Halozyme Therapeutics Inc. compared to the current price of 60.24 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | -1.340% | -9.982% | 0.200% | 10.168% | 2.799% | 30.602% | 51.319% |
| Iovance Biotherapeutics Inc. | 1.220% | 12.889% | 17.326% | -54.209% | 3.204% | -64.989% | -93.712% |
| United Therapeutics | -0.270% | 1.895% | 2.329% | 16.876% | -4.376% | 70.962% | 181.793% |
| Neurocrine Bioscience | -1.900% | 4.400% | -4.922% | -1.266% | -10.569% | 12.933% | 16.688% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
News
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme